SFO
NKTR icon

Standard Family Office’s Nektar Therapeutics NKTR Stock Holding History

Standard Family Office’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3
Closed -$1K – 610
2021
Q1 		$1K Buy
+3
New +$934 ﹤0.01% 554

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Standard Family Office's NKTR Position: Q2 2021 in Review

Standard Family Office sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 3 shares — an estimated $1K sold.

Standard Family Office first reported a position in NKTR in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • Standard Family Office reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Standard Family Office sold 3 Nektar Therapeutics shares in Q2 2021, an estimated $1K.
  • Standard Family Office first reported a position in Nektar Therapeutics in Q1 2021 and held it in 1 quarter.
  • Standard Family Office's Nektar Therapeutics position peaked at $1K in Q1 2021.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Standard Family Office's 13F filing for Q2 2021, filed 13 Aug 2021.